Hence, our findings demonstrated that the plant-produced anti-CTLA-4 2C8 mAb elicited strong antitumor responses and established similar degree of tumor growth inhibition with the commercially available anti-CTLA-4 drug. This evidence concerns the gene CTLA4 and neoplasm.